Prolight Diagnostics (PRLD) investor relations material

Executive summary

• Focused on advancing the Psyros point-of-care (POC) platform to final clinical validation and commercialization, achieving a design freeze for the instrument after the quarter, enabling pilot production and regulatory studies.

• Strong market interest in the Psyros system, with positive feedback from industry and end users, and selection as a semifinalist in the ADLM 2026 Disruptive Technology Award Competition.

• Collaboration with BRAINBox Solutions yielded positive results for traumatic brain injury biomarkers, confirming the platform's broad potential and moving to the next phase of clinical evaluation.

Financial highlights

• Net sales remained at 0 SEK (0 SEK in Q1 2025); other operating income was 1,201 TSEK (1,662 TSEK in Q1 2025).

• Operating profit (EBIT) was -10,389 TSEK (-10,937 TSEK in Q1 2025); profit after tax was -10,389 TSEK (-10,937 TSEK in Q1 2025).

• Earnings per share improved to -0.86 SEK from -1.55 SEK year-over-year.

• Cash flow from operating activities was -12,640 TSEK (-9,176 TSEK in Q1 2025); cash and cash equivalents at quarter-end were 17,262 TSEK (3,173 TSEK in Q1 2025).

• Equity ratio increased to 87% (76% in Q1 2025).

Outlook and guidance

• Upcoming milestones include validating cartridge manufacturing, initiating pilot instrument production, verifying the POC system, and starting the final clinical performance study in Europe and the UK.

• The next phase of the BRAINBox collaboration is fully funded and will analyze 260 clinical samples.